The Food and Drug Administration recently approved the use of a prefilled syringe as an acceptable delivery method for the drug Lucentis.
Lucentis, developed by San Francisco-based Genentech, is intended to treat individuals with wet age-related macular degeneration and macular edema after retinal vein occlusion — two eye conditions that can impair vision and lead to blindness, according to the report.
The prefilled syringe cuts several steps out of the preparation and administration process for physicians, according to the report.
Genentech expects it to hit the market in early 2017.
More articles on supply chain:
Trucking industry provides less financial support to Donald Trump than past Republican nominees: 4 things to know
Drug industry, hospitals fight over 340B drug pricing program
6 latest FDA approvals